Merck's Getting Out of Medco....Not
Executive SummarySuperficially, Merck’s sale of Medco Behavioral to management and Kohlberg Kravis sounds like the first rumblings of disappointment in Medco. It isn’t.
You may also be interested in...
Company says it has learnt from gene therapy flop Glybera, and claims best-in-class status for viral vector.
Softening provisions to make EU-wide joint clinical assessments voluntary would make proposed legislation on HTA cooperation redundant, says Eurordis.